- Home
- ZYME vs MFP Comparison
ZYME vs MFP Comparison
Compare ZYME & MFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | MFP |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ZYME | MFP |
|---|---|---|
| Price | $26.56 | $42.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $38.90 | N/A |
| AVG Volume (30 Days) | ★ 514.3K | 397.5K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $183.10 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $16.00 | $40.00 |
| 52 Week High | $31.34 | $52.58 |
Technical Indicators
Market Signals| Indicator | ZYME | MFP |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 45.20 |
| Support Level | $22.10 | $40.92 |
| Resistance Level | $27.30 | $49.11 |
| Average True Range (ATR) | 0.99 | 2.14 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 24.20 | 42.67 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.